Study wrapper · #153
The Efficacy of Glucagon-like Peptide-1 Based Therapies in Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis.
Editor's note
This systematic review and meta-analysis (14 RCTs, 15,180 participants, rated low risk of bias, PROSPERO-registered) pools GLP-1-based therapies — including tirzepatide — across the heart-failure spectrum. Researchers reported a modest reduction in heart-failure hospitalisation overall (RR 0.84, 95% CI 0.71–0.99), with a larger signal in HFpEF patients with stable coronary disease (RR 0.61) and in the composite of hospitalisation plus cardiovascular death for HFpEF (RR 0.67). A meta-analysis sits high on the evidence hierarchy, but it inherits the limits of its inputs: the subgroup effects rest on fewer trials with wider intervals, and the exenatide-in-HFmrEF finding is explicitly flagged as limited. This aligns with tirzepatide's registration-grade base and the emerging cardiovascular picture, but the authors frame effects as phenotype-specific rather than universal. Weigh it as supportive, hypothesis-refining evidence.
Plain-language abstract
Heart failure comes in several types, defined by how well the heart pumps (its ejection fraction). Researchers combined 14 randomised controlled trials — the highest-quality trial design — covering 15,180 people, to see how medications based on the gut hormone GLP-1 (a group that includes tirzepatide) affect heart outcomes. Pooling the data, they found these drugs were associated with fewer hospital admissions for heart failure overall, and the benefit looked strongest in people with 'preserved ejection fraction' heart failure who also had stable coronary artery disease. There was also a signal toward fewer cardiovascular deaths in younger people with reduced-pump heart failure. The authors caution that benefits appeared to depend on the specific type of heart failure, and that some findings came from only a few trials with less certainty. They conclude the effects look specific to the type of heart failure rather than the same for everyone.